Vcreate

Biotechnology Research

Designing the next generation of T-cell immunotherapies

View all 8 employees

Über uns

Website: https://vcreate.io
External link for Vcreate
Industrie: Biotechnology Research
Größe des Unternehmens: 2-10 Mitarbeiter
Typ: In Privatbesitz

Employees at Vcreate

Oleg Rogynskyy

Founder & CEO - SalesAI for Fortune500 ($200M, Andreessen, Iconiq, Lightspeed, YC - HIRING SALES LEADERS, AEs & ENGINEERS)
Gunsagar Gulati

Clinical Fellow in Hematology/Oncology at Dana-Farber Cancer Institute

Alle Mitarbeiter sehen

Aktualisierungen

Vcreate

233 followers
2w
Diesen Beitrag melden
Keep building!
Binbin Chen, MD, PhD

CEO, Co-founder at Vcreate.io
2w

Thanks to Merck Digital Science Studio for their support over the past ten months. We are grateful for the opportunity to connect with so many amazing founders, scientists, and investors all along the way. Sample pictures from our final demo day. Excited to meet our cohort 3 in the future! Ahmet Hamdi Cavusoglu Geof Hannigan, PhD Anita Manik, MBA, CPA Juan Alvarez Camella Wilson, PhD Prem Tumkosit, Carrie Williams, Northpond Ventures Microsoft for Startups Merck Global Health Innovation Fund, NJIT
Wie Kommentar Aktie
Vcreate

233 followers
3w
Diesen Beitrag melden
Binbin Chen, MD, PhD

CEO, Co-founder at Vcreate.io
3w Bearbeitet

This is a big deal: the first FDA-approved engineered cell therapy for solid tumors. What's more: it's for a patient population with urgent unmet needs!

Adaptimmune Receives U.S. FDA Accelerated Approval of TECELRA® (afamitresgene autoleucel), the First Approved Engineered Cell Therapy for a Solid Tumor

businesswire.com

Wie Kommentar Aktie
Vcreate

233 followers
4mo
Diesen Beitrag melden
We are excited to welcome Jonathan Schneck MD/PhD, Professor at Johns Hopkins Medicine and co-founder of NexImmune Inc. (NASDAQ: NEXI), to the Scientific Advisory Board of Vcreate. A pioneer in T cell biology, Dr. Schneck has developed crucial technologies such as artificial antigen presenting cells and artificial lymph nodes for advanced cancer immunotherapy. Technologies from the Schneck Lab enable the field to better activate and engineer anti-cancer T cells in vivo. We look forward to working with Dr. Schneck to advance our platform and build our asset portfolio. Dr. Schneck will join our other amazing advisors, including Russ Altman Eric Horvitz Lisa Wagar Michael Khodadoust Richard Yu Hanadie Yousef Gunsagar Gulati Ron Alfa, MD, PhD
13 Comments

Wie Kommentar Aktie

Jobs durchsuchen

Finanzierung

Vcreate 1 total round

Letzte Runde

Pre seed Jun 6, 2021

Siehe mehr Informationen auf crunchbase

Vcreate

Biotechnology Research

Designing the next generation of T-cell immunotherapies

Über uns

Employees at Vcreate

Oleg Rogynskyy

Founder & CEO - SalesAI for Fortune500 ($200M, Andreessen, Iconiq, Lightspeed, YC - HIRING SALES LEADERS, AEs & ENGINEERS)

Gunsagar Gulati

Clinical Fellow in Hematology/Oncology at Dana-Farber Cancer Institute

Aktualisierungen

Adaptimmune Receives U.S. FDA Accelerated Approval of TECELRA® (afamitresgene autoleucel), the First Approved Engineered Cell Therapy for a Solid Tumor

businesswire.com

Werden Sie jetzt Mitglied und sehen Sie, was Sie verpassen

Ähnliche Seiten

Ascent Bio

Aperture Bio

Orbits Oncology

Prism.bio

Serinus Biosciences

Brainify.AI

Readout AI

DANNCE.ai

Nash

vCreate

Jobs durchsuchen

Account Manager Stellenangebote

Ingenieur Jobs

Wordpress Developer jobs

Wissenschaftler Jobs

SQL Entwickler Jobs

Media Executive jobs

Finanzierung